SANA SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 10, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 11, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Sana Biotechnology Reports Q3 2026 Financial Results and Provides Pipeline and Clinical Updates

Nov 5, 2026

8-K

Sana Biotechnology Corporate Presentation Outlines Clinical Progress in Hypoimmune Islet Cell Therapies and In Vivo CAR T Platforms

Sep 8, 2026

8-K

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

Aug 10, 2026

8-K

Sana Biotechnology, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 5, 2026

8-K

Sana Biotechnology, Inc. Completes Common Stock Offering

May 15, 2026

8-K

Sana Biotechnology Reports Q1 2026 Financial Results and Strategic Collaboration with Mayo Clinic

May 11, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Apr 13, 2026

424B5

REGISTERED OFFERING

Aug 7, 2025

424B5

PENDING FIXED PRICE OFFERING

Aug 6, 2025

424B5

May 2025 ATM

May 8, 2025

424B5

17,272,728 Shares of Common Stock

Feb 8, 2024

424B5

Common Stock

Feb 7, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 11, 2026

S-3ASR

March 2026 SHELF + ATM

Mar 3, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 8, 2025

POS AM

Form POS AM - Post-Effective amendments for registration statement

Mar 17, 2025

POSASR

Form POSASR - Post-effective Amendment to an automatic shelf registration statement

Mar 14, 2025

S-8

Registration

May 8, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 25, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 5, 2026

Bishop Hans Edgar (Reporting)

Oct 6, 2026

PATEL DHAVALKUMAR DHIRAJLAL (Reporting)

Aug 27, 2026

SCHEDULE 13G/A

ARCH Venture Fund IX, L.P. (Filed by)

Aug 14, 2026

Bishop Hans Edgar (Reporting)

Jul 7, 2026

Yang Patrick Y (Reporting)

Jun 5, 2026

Other

TYPE

HEADLINE

FILED AT

Sana Biotechnology, Inc. SANA · SEC Filings